Literature DB >> 29923351

EndophilinA2 protects against angiotensin II-induced cardiac hypertrophy by inhibiting angiotensin II type 1 receptor trafficking in neonatal rat cardiomyocytes.

Yun Liu1,2, Huan-Jia Shen1, Xin-Qiu-Yue Wang1, Hai-Qi Liu1, Ling-Yun Zheng3, Jian-Dong Luo2.   

Abstract

Cardiac hypertrophy is one of the major risk factors for chronic heart failure. The role of endophilinA2 (EndoA2) in clathrin-mediated endocytosis and clathrin-independent endocytosis is well documented. In the present study, we tested the hypothesis that EndoA2 protects against angiotensin II (Ang II)-induced cardiac hypertrophy by mediating intracellular angiotensin II type 1 receptor (AT1-R) trafficking in neonatal rat cardiomyocytes (NRCMs). Cardiac hypertrophy was evaluated by using cell surface area and quantitative RT-PCR (qPCR) analyses. For the first time, we found that EndoA2 attenuated cardiac hypertrophy and fibrosis induced by Ang II. Moreover, EndoA2 inhibited apoptosis induced by excessive endoplasmic reticulum stress (ERS), which accounted for the beneficial effects of EndoA2 on cardiac hypertrophy. We further revealed that there was an interaction between EndoA2 and AT1-R.The expression levels of EndoA2, which inhibits AT1-R transport from the cytoplasm to the membrane, and the interaction between EndoA2 and AT1-R were obviously decreased after Ang II treatment. Furthermore, Ang II inhibited the co-localization of AT1-R with GRP-78, which was reversed by EndoA2 overexpression. In conclusion, our results suggested that EndoA2 plays a role in protecting against cardiac hypertrophy induced by Ang II, possibly by inhibiting AT1-R transport from the cytoplasm to the membrane to suppress signal transduction.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiotensin II; angiotensin II type 1 receptor trafficking; cardiac hypertrophy; endophilinA2; neonatal rat cardiomyocytes

Mesh:

Substances:

Year:  2018        PMID: 29923351     DOI: 10.1002/jcb.26862

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

1.  Endophilin A2 attenuates cardiac hypertrophy induced by isoproterenol through the activation of autophagy.

Authors:  Xin-Qiu-Yue Wang; Zong-Tang Xu; Gui-Ping Zhang; Ning Hou; Qin-Xing Mo; Jie Wei; Xin Jiang; Yun Liu; Jian-Dong Luo
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

2.  Inhibiting SLC26A4 reverses cardiac hypertrophy in H9C2 cells and in rats.

Authors:  Liqun Tang; Xiaoqin Yu; Yangyang Zheng; Ning Zhou
Journal:  PeerJ       Date:  2020-01-21       Impact factor: 2.984

3.  Circ-SIRT1 inhibits cardiac hypertrophy via activating SIRT1 to promote autophagy.

Authors:  Weichen Wang; Longlong Wang; Mengyue Yang; Chunwei Wu; Rui Lan; Weiwei Wang; Yuze Li
Journal:  Cell Death Dis       Date:  2021-11-10       Impact factor: 8.469

4.  Endophilin A2-mediated alleviation of endoplasmic reticulum stress-induced cardiac injury involves the suppression of ERO1α/IP3R signaling pathway.

Authors:  Yun Liu; Ruixiang Hu; Huanjia Shen; Qinxin Mo; Xinqiuyue Wang; Guiping Zhang; Sujuan Li; Guanfeng Liang; Ning Hou; Jiandong Luo
Journal:  Int J Biol Sci       Date:  2021-08-26       Impact factor: 6.580

5.  Cholecystokinin Expression in the Development of Myocardial Hypertrophy.

Authors:  Zhongshu Han; Sheng Bi; Yongsheng Xu; Xiaoying Dong; Lixia Mei; Hailong Lin; Xueqi Li
Journal:  Scanning       Date:  2021-08-21       Impact factor: 1.932

6.  Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.

Authors:  Xiaoying Wang; Kai He; Linlin Ma; Lan Wu; Yan Yang; Yanfei Li
Journal:  Mol Med Rep       Date:  2022-08-10       Impact factor: 3.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.